Optometry 360
  • Home
  • Conferences
  • Videos
  • About Us
    • About Us – Mission
    • Media Partners
    • Advisory Board
    • Industry Council
    • Business Team

What are you looking for?

  • Conference Roundup
  • Contact Lenses
  • Diagnostics
  • Glaucoma
  • Myopia
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Retina
  • Spotlight Series
Navigating Presbyopia Conversations with Patients in Practice
Optometry 360
  • Home
  • Conferences
  • Videos
  • About Us
    • About Us – Mission
    • Media Partners
    • Advisory Board
    • Industry Council
    • Business Team
Home > DIMS spectacle lenses noninferior to orthokeratology for slowing myopia progression in children
  • Contact Lenses

DIMS spectacle lenses noninferior to orthokeratology for slowing myopia progression in children

Optometry 360

Defocus Incorporated Multiple Segments (DIMS) spectacle lenses were noninferior to orthokeratology lenses (OKL) for slowing axial elongation in myopic children after 18 months of treatment, according to a study.

The randomized clinical trial included 90 children aged 6 to 12 years who were randomized to DIMS spectacle lenses (n = 45) or OKL (n = 45). The primary outcome was axial length growth after 18 months. The adjusted between-group difference in axial elongation was −0.05 mm (95% CI, −0.13 to 0.04), which met the prespecified noninferiority margin.

Defocus Incorporated Multiple Segments lenses were not superior to OKL. Overall eye length elongation also did not differ significantly between groups, with a between-group difference of −0.04 mm (95% CI, −0.12 to 0.04). One adverse event was reported in the OKL group.

Reference
Andersen LC, Mejldal A, Sivakumar S, et al. Defocus incorporated multiple segment spectacle lenses versus orthokeratology lenses for myopia control: a non-inferiority randomised clinical trial. BMC Ophthalmol. 2026;26(1):488. doi: 10.1186/s12886-026-05144-6. PMID: 42595991; PMCID: PMC13471525.

Share

Related Content

  • Myopia

Theialife plans Phase 3 trials of oral ND10 for progressive pediatric myopia

  • Myopia

High-dose atropine plus dual-focus lenses show minimal myopia progression

  • Myopia

Myopia Action Month: empowering practices to take the next step in myopia management

  • Myopia

New tool measures parents’ knowledge and practices related to myopia prevention

  • Myopia

Low-dose atropine linked to sustained myopia control and minimal rebound

  • Myopia

Long-term DIMS lens users report high satisfaction despite cost barrier

Share

Advisory Board

Kaleb Abbott, OD, MS, FAAO

Clark Chang, OD

Jessica Haynes, OD, FAAO, FORS, Dipl ABO

Monica Kalia, OD

Cecelia Koetting, OD, FAAO, DipABO

Roya Attar, OD, MBA, DHA, FAAO

Hardeep Kataria, OD, FAAO

Marc R. Bloomenstein, OD, FAAO

Elise Kramer, OD

See All
Optometry 360

Optometry 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

© 2026 Optometry 360 is a trademark of International Healthcare Media, LLC. All rights Reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophthalmology360 Icon